Deal Details

Private Placement

Healthcare

Private Placement

Summary

Baird served as a co-placement agent on this offering

About

Genocea Biosciences, Inc. (“Genocea”) (NASDAQ: GNCA) recently announced a Private Investment in Public Equity (“PIPE”) offering of 21.4 million shares of its common stock and 12.2 million pre-funded warrants to purchase its common stock, along with accompanying warrants to purchase one share of common stock for each share of common stock or pre-funded warrant purchased by an investor. The warrants will be exercisable immediately upon issuance at an exercise price of $2.25 per share and have a 4-year term. The gross proceeds to Genocea from the offering are expected to be up to approximately $80 million.

Genocea’s mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Its unique ATLAS™ platform comprehensively profiles each patient’s T cell responses to potential targets, or antigens, on the tumor. ATLAS enables Genocea to optimize the neoantigens for inclusion in its immunotherapies and exclude inhibitory antigens that can exert an immunosuppressive effect. Genocea is advancing two ATLAS-enabled programs: GEN-009, its neoantigen vaccine for which Genocea is conducting a Phase 1/2a clinical trial and expect preliminary clinical results in the third quarter of 2020, and GEN-011, its neoantigen-specific cell therapy using T cells derived from peripheral blood for which Genocea expects to conduct a Phase 1/2a clinical trial. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts.

Healthcare

Private Placement